These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30824559)

  • 1. Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.
    Trenkwalder C; Kuoppamäki M; Vahteristo M; Müller T; Ellmén J
    Neurology; 2019 Mar; 92(13):e1487-e1496. PubMed ID: 30824559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
    Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
    Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
    Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.
    Tolosa E; Hernández B; Linazasoro G; López-Lozano JJ; Mir P; Marey J; Kulisevsky J
    J Neural Transm (Vienna); 2014 Apr; 121(4):357-66. PubMed ID: 24253234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
    Martínez-Martín P; Hernández B; Ricart J;
    Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
    Lew MF; Somogyi M; McCague K; Welsh M;
    Int J Neurosci; 2011 Nov; 121(11):605-13. PubMed ID: 21843110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
    Groenendaal H; Tarrants ML; Armand C
    Clin Drug Investig; 2010; 30(11):789-98. PubMed ID: 20818839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
    Eggert K; Skogar O; Amar K; Luotonen L; Kuoppamäki M; Leinonen M; Nissinen H; Oertel W
    J Neural Transm (Vienna); 2010 Mar; 117(3):333-42. PubMed ID: 20013007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone.
    Park J; Kim Y; Youn J; Lee PH; Sohn YH; Koh SB; Lee JY; Baik JS; Cho JW
    Neurol India; 2017; 65(4):746-751. PubMed ID: 28681744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
    Giladi N; Gurevich T; Djaldetti R; Adar L; Case R; Leibman-Barak S; Sasson N; Caraco Y
    Parkinsonism Relat Disord; 2021 Oct; 91():139-145. PubMed ID: 34619438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.
    Lyons KE; Pahwa R
    Clin Neuropharmacol; 2006; 29(2):73-6. PubMed ID: 16614538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
    Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
    Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.
    Rinne UK; Larsen JP; Siden A; Worm-Petersen J
    Neurology; 1998 Nov; 51(5):1309-14. PubMed ID: 9818851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
    Delea TE; Thomas SK; Hagiwara M; Mancione L
    Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H; Emre M
    Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.